Home General Physiology and Biophysics 2011 General Physiology and Biophysics Vol.30, No.4, p.329–341, 2011

Journal info


Founded: 1982
ISSN 1338-4325 (online)
ISSN 0231-5882 (print)
Published in English,
6 times per year

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

General Physiology and Biophysics Vol.30, No.4, p.329–341, 2011

Title: The role of PPAR in myocardial response to ischemia in normal and diseased heart
Author: Tana Ravingerova, Adriana Adameova, Slavka Carnicka, Martina Nemcekova, Tara Kelly, Jana Matejikova, Eleftheria Galatou, Eleftheria Barlaka, Antigone Lazou

Abstract: Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors, belong to the nuclear hormone receptor superfamily regulating expression of genes involved in different aspects of lipid metabolism, inflammation and cardiac energy production. Activation of PPAR-α isoform by its natural ligands, fatty acids (FA) and eicosanoids, promotes mitochondrial FA oxidation as the primary ATP-generating pathway. On the other hand, PPAR-γ regulates lipid anabolism or storage, while, until recently, the function of PPAR-β/δ has been less explored. Under conditions associated with acute or chronic oxygen deprivation, PPAR-α modulates expression of genes that determine substrate switch (FA vs. glucose) aimed at maintenance of basic cardiac function. Although PPAR-α and PPAR-γ synthetic agonists, hypolipidemic and antidiabetic drugs, have been reported to protect the heart against ischemia/reperfusion injury, it is still a matter of debate whether PPAR activation plays a beneficial or detrimental role in myocardial response to ischemia, in particular, in pathological conditions. This article reviews some findings demonstrating the impact of PPAR activation on cardiac resistance to ischemia in normal and pathologically altered heart. Specifically, it addresses the issue of susceptibility to ischemia in the diabetic myocardium, with particular regards to the role of PPAR. Finally, involvement of PPAR in the mechanisms of lipid-independent cardioprotective effects of some hypolipidemic drugs is also discussed.

Keywords: Peroxisome proliferator-activated receptors — Myocardial ischemia — Cardioprotection — Hypolipidemic drugs — HMG-CoA reductase inhibitors — Pleiotropic effects
Year: 2011, Volume: 30, Issue: 4 Page From: 329, Page To: 341
doi:10.4149/gpb_2011_04_329


download file



more categories


2011 Special Issue

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.